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ORGAN FUNCTION AND QUALITY OF LIFE CORRELATES AT RANDOMIZA-
TION ON THE SCOT (SCLERODERMA: CYCLOPHOSPHAMIDE OR
TRANSPLANTATION) TRIAL
Sullivan, K.M.1, Froshaug, D.B.2, Furst, D.E.3, Nash, R.A.4,
Mayes, M.D.5, Crofford, L.J.6, McSweeney, P.A.7, Goldmuntz, E.A.8,
Keyes-Elstein, L.2, Khanna, D.3 1Duke University Medical Center,
Durham, NC; 2Rho Federal System, Chapel Hill, NC; 3University of
California-Los Angeles, Los Angeles, CA; 4Fred Hutchinson Cancer
Research Center, Seattle, WA; 5University of Texas-Houston, Houston,
TX; 6University of Kentucky, Lexington, KY; 7Rocky Mountain Cancer
Centers, Denver, CO; 8National Institutes of Health, Bethesda, MD
Objective:Autoimmune diseases offer unique opportunities to mea-
sure disease burden and response to immunomodulation with hema-
topoietic cell transplantation (HCT). To study baseline impairments
in health-related quality of life (HR-QOL), we analyzed correlates of
HR-QOL indices among patients with diffuse systemic sclerosis
(SSc) participating in the SCOT trial.
Methods: Subjects with poor prognosis SSc were enrolled in the on-
going multicenter trial comparing immunosuppression with 12
monthly infusions of CY (750mg/m2) vs. immunoablation followed
by CD34-selected autologous HCT. Entry criteria are detailed at
the study website (www.sclerodermatrial.org). Validated HR-QOL
indices included the short form 36 (SF-36) physical component sum-
mary (PCS) and mental component summary (MCS), health assess-
ment questionnaire-disability index (HAQ-DI), and the UCLA
gastrointestinal instrument (GIT 2.0). We assessed Pearson correla-
tions between HR-QOL indices and objective disease measures:
coefficients. /5 0.32 (representing R2. /5 10%) were considered
meaningful associations.
Results: 61 subjects were evaluated before treatment: 40 were fe-
male; mean age was 46 and disease duration was 3.8 yr; mean
(SD) % predicted FVC was 74.6 (16.2) and DLCO was 50.5
(8.2). Mean modified Rodnan Skin Score (mRSS) was 30.9 (9.5).
mRSS measures dermal thickening ranging from 0 (none) to 51
(total body sclerosis). Baseline mean PCS was 27.4 which is 2.3
SD below the US general population. The 61 patients had moder-
ate functional disability (mean HAQ-DI 1.4) while the mean total
GIT (measured in 21 pts) was 0.76, where 0.4 signifies moderate se-
verity. For comparison, subjects with diffuse SSc enrolled in the
Scleroderma Lung Study (comparing CY with placebo, Tashkin
NEJM 2006) had a higher (better) baseline PCS (32.1) and
lower (better) HAQ-DI (1.02) (Khanna Arthritis Rheum 2005).
The table presents Pearson’s correlations between HR-QOL indi-
ces and mRSS, FVC and DLCO. Correlations (r) with magnitudes
of . / 5 0.32 are bolded.
Table 1. Baseline Pearson’s Correlation Coefficients (r) for
HR-QOL Measures versus Dermal and Pulmonary Measures
Variables mRSS1 FVC2 DLCO2SHAQ
HAQ-DI1 0.58* 0.02 -0.41*
Pain VAS1 0.05 0.05 0.00
SF-36
SF-36 PCS 2 -0.47* 0.02 0.25
SF-36 MCS2 -0.03 0.08 0.13
SF-36 Physical functioning2 -0.47* 0.10 0.45*
SF-36 Role limitations2 -0.40* -0.01 0.31*
SF-36 Pain 2 -0.20 0.10 0.08
SF-36 General health 2 -0.15 -0.07 0.07
SF-36 Vitality2 -0.12 0.11 0.06
SF-36 Social functioning 2 -0.17 0.00 0.07
SF-36 Role emotional 2 -0.15 0.10 0.25
SF-36 Mental health2 -0.04 0.01 0.17(Continued )Table 1. (Continued )Variables mRSS1 FVC2 DLCO2UCLA GIT 2.0
Reflux scale1 -0.34* 0.32 0.24
Distention scale1 -0.47* 0.27 0.41
Diarrhea1 0.09 -0.13 -0.23
Constipation1 0.08 -0.11 -0.30
Emotional well-being1 -0.13 -0.05 0.07
Social functioning1 0.07 0.33 -0.23
GIT Total Score -0.29 0.24 0.171Lower scores denote better HR-QOL or lower intensity of symptoms.
2Higher scores denote better HR-QOL or lower intensity.
*Correlations significant at p<0.05. %R 2 >10% (r>0.32) are bolded.
Conclusions:Patients in the SCOT study had marked baseline im-
pairments in physical health. Objective disease measures of dermal
and pulmonary involvement correlated with symptom burden.
Longitudinal analysis (12 test repetitions over 72 mo) at study
completion will offer unique rigor in HCT trials, provide a rich
basis for comparisons with immune and mechanistic studies, and
characterize alterations in HR-QOL indices across the two treat-
ments of SSc.AUTOLOGOUS TRANSPLANTS114
DOUBLE HIGH DOSE SALVAGE THERAPY WITH DOSE-INTENSIFIED
CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (DICEP) RE-INDUC-
TION FOLLOWED BY HIGH-DOSE MELPHALAN (HDM) AND AUTOLO-
GOUS STEM CELL TRANSPLANTATION (ASCT) CONSOLIDATION FOR
RELAPSED/REFRACTORY HODGKIN LYMPHOMA
Shafey, M., Duan, Q., Russell, J.A., Duggan, P., Balogh, A.,
Stewart, D.A. University of Calgary, Tom Baker Cancer Centre, Calgary,
AB, Canada
The purpose of this study was to retrospectively review our results
of double high-dose therapy with DICEP re-induction followed by
HDM and ASCT for this patient population.
Between June 1995 andNovember 2009, 73 patients with relapsed
(43) or refractory (30) classical HL were treated with DICEP (dose-
intensified cyclophosphamide 5.25 g/m2, etoposide 1050 mg/m2,
and cisplatin 105 mg/m2) with autologous blood stem cell apheresis
performed upon hematopoietic recovery, followed 2-3 weeks later by
HDM (melphalan 200 mg/m2) and ASCT.
Patient characteristics included: age 20-63 years (median 37);
bulk. 5 cm5 39, bulk. 10 cm5 12; number of prior chemother-
apy regimen(s) failed 15 63, 2-45 10; prior radiotherapy5 30; ini-
tial time to progression\3months5 30, 3-12 months5 21, and.
12 months 5 22; median time from diagnosis to ASCT 15 months
(range 4-324); B symptoms 5 18; and International Prognostic
Score (IPS) 0-15 19, 25 26, 35 17, 4-75 11. DICEP chemother-
apy resulted in successful stem cell mobilization in 71 patients
(97%), with a median CD341 cell count of 15.6 x106/kg (range
4.7-70.9 x106/kg). 63 patients (86%) responded to DICEP, includ-
ing 13 complete responses (18%). 4 patients did not proceed to
HDM-ASCT; two failed to mobilize stem cells, one experienced
grade IV infection, and one experienced bleeding and respiratory
arrest with anoxic brain injury following removal of an internal
jugular apheresis catheter following stem cell collection. The latter
patient was the only treatment-related death following DICEP.
With a median follow-up of 56 months post-DICEP (range 3-
170 months), the 5-year PFS and OS rates were 61% [95%CI 5
49-72%] and 80% [95%CI 5 69-89%], respectively. The 5 year
PFS was 65% vs. 30% for DICEP responders vs. non-respondersS195
S196 Poster Session I(logrank p 5 0.003), and 89% for IPS score 5 0-1, 56% for IPS 5
2-3, and 24% for IPS 5 4-7 (logrank p\ 0.001). Response to DI-
CEP and relapse IPS were the only two factors that independently
predicted PFS and OS in multivariate analysis. Of the 26 patients
who relapsed following DICEP6HDM/ASCT, 7 (27%) achieved
subsequent long-term PFS of $ 3 years using radiotherapy
(n 5 1), chemotherapy and radiotherapy (n 5 2), or allogeneic
SCT (n 5 4).
DICEP-HDM/ASCT for relapsed/refractory Hodgkin lym-
phoma is associated with excellent stem cell mobilization capability
and favourable PFS and OS outcomes. These results compare
favourably to previously reported alternative regimens and require
validation in a prospective multi-centre clinical trial.115
ANOVEL HIGHDOSE CHEMOTHERAPY STRATEGYWITH BENDAMUSTINE
IN ADJUNCT TO ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM)
FOLLOWED BY AUTOLOGOUS STEM CELL RESCUE IS SAFE AND HIGHLY
EFFECTIVE FOR THE TREATMENT OF RESISTANT/RELAPSED LYMPHOMA
PATIENTS: A PHASE I-II STUDY ON 44 PATIENTS
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BEAM (Carmustine, etoposide, cytarabine, and melphalan) is the
most used conditioning regimen before autologous stem cell trans-
plant (ASCT) in lymphoma patients. However, relapse rate after
transplant is still a matter of concern. Therefore, new regimens
with a higher efficacy are particularly needed.
We designed a phase I-II study to evaluate the safety and the effi-
cacy of increasing doses of Bendamustine for the conditioning regi-
men to ASCT for resistant/relapsed lymphoma patients. As
a biological background, we performed in vitro experiments which
showed the synergistic activity of bendamustine with etoposide, ara-
cytin and melphalan in lymphoma cell lines.
Forty-four patients (median age 47 years) with resistant/relapsed
non-Hodgkin (29) or Hodgkin (15) lymphoma were consecutively
enrolled in the study. The new regimen consisted of increasing doses
of Bendamustine coupled with fixed doses of Etoposide (200mg/m2/
day on days -5 to -2), Cytarabine (400mg/m2 on days -5 to -2) and
Melphalan (140 mg/m2 on day -1) (BeEAM regimen). The study
was registered at EMEA with the EUDRACT no 2008-002736-
15. The starting dose of Bendamustine was 160 mg/m2/daily given
on days -7 and -6, which was then escalated according to the Fibo-
nacci’s increment rule until the onset of severe adverse events and/
or the attainment of the expected MTD, but not higher than 200
mg/m2.
The administration of Bendamustine was safe in all the 3 cohorts
of 3 patients. We then fixed the dose of Bendamustine 200 mg/m2 as
safe and effective for the Phase II study.
A median number of 5.68x106CD341/kg cells (range 2.4-15.5) col-
lected from peripheral bloodwas reinfused to patients. All patients en-
grafted, with a median time to ANC . 0.5x109/l of 10 days. Median
times to achieve a platelet count . 20x109/l and . 50x109/l were 13
and16days respectively.Twenty-twoout of 44 patients presented a fe-
ver of unknown origin. All patients received G-CSF after transplant
for a median time of 9 days (range: 8-25).
39/44 patients are evaluable for the response to treatment. After
a median follow-up of 14 months from transplant, 32/39 patients
are in complete remission, whereas 4/39 are in partial response. 3/
39 patients relapsed after a median time of 3 months from transplant.
Remarkably, 4/39 patients achieved the first complete remission af-
ter receiving the high-dose therapy with ASCT.
In conclusion, the new BeEAM regimen is safe and seems to have
a high efficacy in heavily pretreated lymphoma patients.116
NORDIC MCL2 TRIAL OF 1ST-LINE INTENSIVE IMMUNOCHEMOTHERAPY
AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL
LYMPHOMA: STILL ENCOURAGING RESULTS AFTER MEDIAN 5½ YEARS
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Mantle cell lymphoma (MCL) has a poor prognosis with a median
survival of 5 years based on conventional immunochemotherapy. In
spite of the high risk characteristics of the 160 patients of the Nordic
MCL2 Trial of 1.-line intensive immunochemotherapy followed by
BEAM and autologous stem cell transplantation (31% with high Ki-
67 expression, 19% blastoid/pleomorphic), the first results based on
three years median observation were encouraging, including no re-
lapses after 5 years1. In the present update based on median 5.6 years
observation, the 10-year overall survival (OS) is 58%. Late relapses
have decreased the 10-year event-free survival (EFS) and response
duration (RD) to 35% and 46%, respectively. An example of a late
relapse was an isolated CNS relapse in a patient otherwise in persis-
tent complete remission 9.5 years after initial treatment. The mantle
cell lymphoma International prognostic index (MIPI)2, previously
found of prognostic value in our cohort3, remained highly predictive
of OS, EFS and RD. Particularly theMIPI-biological, incorporating
Ki-67, identified 20% of the patients still relapse-free from 3.4 years
to now 9 years posttransplant. Amolecularmarker was available in 71
of the 145 responding patients who completed treatment and had
follow-up samples for minimal residual disease. Molecular response
duration of less than one year posttransplant corresponded to
a shorter clinical response duration (median 4.2 years) than molecu-
lar response duration . 1 year (median 9 years clinical response
duration). In conclusion, the 58% 10-year survival of this high-risk
cohort is still very encouraging, but late relapses do occur, warrant-
ing long-term control and trials of maintenance treatment in this
disease.
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MINIMIZING THE COST OF CURRENT INEFFECTIVE MOBILIZATIONS:
DOUBLING FILGRASTIM ON DAY 4 OF FILGRASTIM-ALONE MOBILIZA-
TION FOR AUTOLOGOUS PERIPHERAL STEM CELL COLLECTION
REDUCES THE USE OF PLERIXAFOR
Betcher, J.A., Torloni, A.S., Befort, C.K., Slack, J.L., Leis, J.F.,
Adams, R.H., Mikhael, J.R. Mayo Clinic in Arizona, Phoenix, AZ
Background: Autologous stem cell mobilization with colony stimu-
lating factors alone has a failure rate of approximately 20%. Plerixa-
for is a stem cell mobilizer effective in increasing the number of
peripheral CD34 cells collected by hematopoetic progenitor cell
apheresis (HPC-A) while reducing the number of HPC-A days in
